$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000109355713000036 Filed on May 01, 2013

Income Statement

Concept	2013 Q1	2012 Q1
Revenue	$29.60M	$20.10M
YoY Change	47.26%	41.55%
Cost Of Revenue	$13.10M	$10.70M
YoY Change	22.43%	17.58%
Gross Profit	$16.50M	$9.400M
YoY Change	75.53%	84.31%
Gross Profit Margin	55.74%	46.77%
Selling, General & Admin	$18.10M	$15.40M
YoY Change	17.53%	43.93%
% of Gross Profit	109.7%	163.83%
Research & Development	$9.300M	$9.400M
YoY Change	-1.06%	49.21%
% of Gross Profit	56.36%	100.0%
Depreciation & Amortization	$1.800M	$1.200M
YoY Change	50.0%	50.0%
% of Gross Profit	10.91%	12.77%
Operating Expenses	$27.40M	$24.80M
YoY Change	10.48%	45.88%
Operating Profit	-$10.90M	-$15.40M
YoY Change	-29.22%	29.41%
Interest Expense	$200.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$11.10M	-$15.40M
YoY Change	-27.92%	29.41%
Income Tax	$0.00	-$1.300M
% Of Pretax Income
Net Earnings	-$11.10M	-$14.10M
YoY Change	-21.28%	19.49%
Net Earnings / Revenue	-37.5%	-70.15%
Basic Earnings Per Share
Diluted Earnings Per Share	-$159.0K	-$208.0K
COMMON SHARES
Basic Shares Outstanding	69.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.30M	$70.20M
YoY Change	-35.47%	88.2%
Cash & Equivalents	$18.90M	$5.100M
Short-Term Investments	$26.40M	$65.10M
Other Short-Term Assets	$2.200M	$2.100M
YoY Change	4.76%	-40.0%
Inventory	$7.500M	$8.000M
Prepaid Expenses
Receivables	$16.30M	$12.50M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$71.30M	$92.80M
YoY Change	-23.17%	70.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.30M	$16.20M
YoY Change	12.96%	38.46%
Goodwill	$3.200M
YoY Change
Intangibles	$4.000M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$1.200M
YoY Change	-16.67%	200.0%
Total Long-Term Assets	$27.50M	$25.20M
YoY Change	9.13%	106.56%
TOTAL ASSETS
Total Short-Term Assets	$71.30M	$92.80M
Total Long-Term Assets	$27.50M	$25.20M
Total Assets	$98.80M	$118.0M
YoY Change	-16.27%	77.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.200M	$2.000M
YoY Change	10.0%	0.0%
Accrued Expenses	$12.50M	$12.30M
YoY Change	1.63%	78.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$700.0K
YoY Change
Total Short-Term Liabilities	$16.20M	$16.10M
YoY Change	0.62%	38.79%
LONG-TERM LIABILITIES
Long-Term Debt	$6.300M	$0.00
YoY Change
Other Long-Term Liabilities	$2.700M	$2.300M
YoY Change	17.39%	43.75%
Total Long-Term Liabilities	$2.700M	$2.300M
YoY Change	17.39%	43.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.20M	$16.10M
Total Long-Term Liabilities	$2.700M	$2.300M
Total Liabilities	$25.20M	$18.40M
YoY Change	36.96%	39.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$456.7M
YoY Change
Common Stock	$530.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$73.60M	$99.60M
YoY Change
Total Liabilities & Shareholders Equity	$98.80M	$118.0M
YoY Change	-16.27%	77.18%

Cashflow Statement

Concept	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$11.10M	-$14.10M
YoY Change	-21.28%	19.49%
Depreciation, Depletion And Amortization	$1.800M	$1.200M
YoY Change	50.0%	50.0%
Cash From Operating Activities	-$4.500M	-$10.20M
YoY Change	-55.88%	9.68%
INVESTING ACTIVITIES
Capital Expenditures	$1.400M	$2.300M
YoY Change	-39.13%	-227.78%
Acquisitions
YoY Change
Other Investing Activities	$14.00M	$14.00M
YoY Change	0.0%	62.79%
Cash From Investing Activities	$12.60M	$11.70M
YoY Change	7.69%	72.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.700M	$1.100M
YoY Change	145.45%
Debt Paid & Issued, Net	$0.00
YoY Change
Cash From Financing Activities	$2.700M	$1.100M
YoY Change	145.45%	-26.67%
NET CHANGE
Cash From Operating Activities	-$4.500M	-$10.20M
Cash From Investing Activities	$12.60M	$11.70M
Cash From Financing Activities	$2.700M	$1.100M
Net Change In Cash	$10.80M	$2.600M
YoY Change	315.38%	-360.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.500M	-$10.20M
Capital Expenditures	$1.400M	$2.300M
Free Cash Flow	-$5.900M	-$12.50M
YoY Change	-52.8%	66.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	8700000	USD
CY2013Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7500000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3900000	USD
CY2013Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2200000	USD
CY2012Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-300000	USD
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2012	us-gaap	Acquisition Costs AcquisitionCosts	300000	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	530300000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	522600000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4100000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5000000	USD
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10900000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11000000	shares
CY2013Q1	us-gaap	Assets Assets	98800000	USD
CY2012Q4	us-gaap	Assets Assets	106000000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	77600000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	71300000	USD
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	26400000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	40600000	USD
CY2013Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	26400000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	40600000	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	0	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	0	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	0	USD
CY2012Q1	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	2200000	USD
CY2012Q1	us-gaap	Business Acquisition Contingent Consideration Shares Issuable BusinessAcquisitionContingentConsiderationSharesIssuable	357176	shares
CY2012Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Other Noncash Consideration BusinessAcquisitionCostOfAcquiredEntityOtherNoncashConsideration	2200000	USD
CY2012Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Purchase Price BusinessAcquisitionCostOfAcquiredEntityPurchasePrice	6100000	USD
CY2012Q1	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Value Assigned BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned	3900000	USD
CY2012Q4	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Value Assigned BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned	3900000	USD
CY2012Q4	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	1
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18900000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5100000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2500000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10800000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2600000	USD
CY2013Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45300000	USD
CY2012Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	4500000	USD
CY2013Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	13600000	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70900000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69500000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69700000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70700000	shares
CY2013Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2012Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14100000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11100000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12400000	USD
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	9600000	USD
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	13100000	USD
CY2012Q1	us-gaap	Cost Of Revenue CostOfRevenue	10700000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1400000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	600000	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1200000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1800000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2012Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9200000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7200000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	53000000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	1300000	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	300000	USD
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	0	USD
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	2200000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1700000	USD
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2000000	USD
CY2012Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2200000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2013Q1	us-gaap	Goodwill Goodwill	3200000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	16500000	USD
CY2012Q1	us-gaap	Gross Profit GrossProfit	9400000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11100000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15400000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1300000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-600000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-500000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3200000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	800000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1100000	USD
CY2013Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2000000	USD
CY2012Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-600000	USD
CY2012Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-100000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	100000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	100000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	0	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	100000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	200000	USD
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4000000	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4200000	USD
CY2012Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
CY2013Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	200000	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4000000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4500000	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	7500000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	7400000	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2900000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2500000	USD
CY2013Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	600000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	25200000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	29000000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	400000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106000000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98800000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16200000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19500000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2013Q1	us-gaap	Long Term Debt LongTermDebt	7000000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	200000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2300000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2300000	USD
CY2013Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2200000	USD
CY2013Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (“CGM”) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2700000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1100000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11700000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12600000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10200000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4500000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-11100000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-14100000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	24800000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	27400000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10900000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15400000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	9900000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1900000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2600000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2700000	USD
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2700000	USD
CY2012Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
CY2013Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2800000	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3500000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1100000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2012Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2100000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2700000	USD
CY2012Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	6100000	USD
CY2013Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4900000	USD
CY2012Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	26600000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1400000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2300000	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2200000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2000000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2700000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1100000	USD
CY2012Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	40600000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	18900000	USD
CY2012Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	500000	USD
CY2013Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	600000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18900000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18300000	USD
CY2013Q1	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	8900000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9300000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9400000	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-456700000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-445600000	USD
CY2012Q1	us-gaap	Revenues Revenues	20100000	USD
CY2013Q1	us-gaap	Revenues Revenues	29600000	USD
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	18600000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27800000	USD
CY2013Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	700000	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	200000	USD
CY2013Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6300000	USD
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6800000	USD
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15400000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18100000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5000000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4100000	USD
CY2013Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	200000	USD
CY2012Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2012Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2011Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73600000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	77000000	USD
CY2012	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2020-01-01
CY2013Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	900000	USD
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical study expenses, allowances for returned product, allowance for bad debt, deferral period for recognizing revenue on future performance obligations, accounting for the SweetSpot acquisition including contingent consideration, and share-based compensation expense. Excess and obsolete inventories are estimated by identifying the amount of on hand and on order materials compared to expected future sales, taking into account clinical trial and development usage along with new product introductions. Employee bonus estimates are based, in part, on the 2013 bonus plan’s authorized target bonus amounts to be awarded from the bonus pool based on the weighted average achievement of certain objectives. Clinical trial expenses are accrued based on estimates of progress under related contracts and include initial set up costs as well as ongoing monitoring over multiple sites in the U.S. and abroad. An allowance for refunds for returned products is determined by analyzing the timing and amounts of past refund activity and considering the impact of newly introduced products.</font></div></div>
CY2012Q4	us-gaap	Valuation Allowance Amount ValuationAllowanceAmount	151300000	USD
CY2013Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	USD
CY2012Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	USD
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69800000	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67800000	shares
CY2013Q1	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	16300000	USD
CY2012Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	19500000	USD
CY2013Q1	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	900000	USD
CY2012Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	700000	USD
CY2013Q1	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	900000	USD
CY2012Q4	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	1200000	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement BusinessAcquisitionContingentConsiderationSettlement	1100000	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement Shares Issued BusinessAcquisitionContingentConsiderationSettlementSharesIssued	89296	shares
CY2013Q1	dxcm	Business Acquisition Equity Interests Issued Or Issuable Additional Number Of Shares Issuable BusinessAcquisitionEquityInterestsIssuedOrIssuableAdditionalNumberOfSharesIssuable	267880	shares
CY2012Q4	dxcm	Clinical Trials ClinicalTrials	100000	USD
CY2013Q1	dxcm	Clinical Trials ClinicalTrials	0	USD
CY2012Q4	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	1700000	USD
CY2013Q1	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	2000000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2013Q1	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	700000	USD
CY2012Q1	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	1100000	USD
CY2013Q1	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1800000	USD
CY2012Q1	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1500000	USD
CY2012Q1	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	100000	USD
CY2013Q1	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	300000	USD
CY2012Q1	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	-100000	USD
CY2013Q1	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	0	USD
CY2012Q4	dxcm	Line Of Credit Facility Borrowing Base Percentage Of Eligible Accounts LineOfCreditFacilityBorrowingBasePercentageOfEligibleAccounts	0.80
CY2013Q1	dxcm	Maximum Percentage Of Ownership Change To Retain Tax Credit Carryforwards MaximumPercentageOfOwnershipChangeToRetainTaxCreditCarryforwards	0.50
CY2013Q1	dxcm	Option To Renew Lease OptionToRenewLease	P5Y
CY2013Q1	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.040
CY2013Q1	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
CY2013Q1	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2013Q1	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2012Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	500000	USD
CY2013Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	500000	USD
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2013Q1	dxcm	Term Of Lease TermOfLease	P3Y
CY2013Q1	dxcm	Working Capital WorkingCapital	55100000	USD
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70699449	shares
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2013Q1	dei	Trading Symbol TradingSymbol	DXCM

Files In Submission

Name	View Source	Status
0001093557-13-000036-index-headers.html	Edgar Link	pending
0001093557-13-000036-index.html	Edgar Link	pending
0001093557-13-000036.txt	Edgar Link	pending
0001093557-13-000036-xbrl.zip	Edgar Link	pending
dxcm-03312013x10q.htm	Edgar Link	pending
dxcm-20130331.xml	Edgar Link	completed
dxcm-20130331.xsd	Edgar Link	pending
dxcm-20130331_cal.xml	Edgar Link	unprocessable
dxcm-20130331_def.xml	Edgar Link	unprocessable
dxcm-20130331_lab.xml	Edgar Link	unprocessable
dxcm-20130331_pre.xml	Edgar Link	unprocessable
dxcm03312013ex1027.htm	Edgar Link	pending
dxcm03312013ex3101.htm	Edgar Link	pending
dxcm03312013ex3102.htm	Edgar Link	pending
dxcm03312013ex3201.htm	Edgar Link	pending
dxcm03312013ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2013 Q1 Form 10-Q Financial Statement

#000109355713000036 Filed on May 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2013 Q1 Form 10-Q Financial Statement

#000109355713000036 Filed on May 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm